These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 5158077)

  • 1. A controlled evaluation of clinical and metabolic effects of dialysate calcium levels during regular hemodialysis.
    Mirahmadi KS; Duffy BS; Shinaberger JH; Jowsey J; Massry SG; Coburn JW
    Trans Am Soc Artif Intern Organs; 1971; 17():118-24. PubMed ID: 5158077
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of lowering dialysate calcium concentration on serum bone turnover markers in hemodialysis patients.
    Hamano T; Oseto S; Fujii N; Ito T; Katayama M; Horio M; Imai E; Hori M
    Bone; 2005 May; 36(5):909-16. PubMed ID: 15794928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sevelamer hydrochloride and vitamin D for controlling serum calcium, phosphorus and bone metabolism in patients undergoing hemodialysis].
    Ishida M; Yao N; Yachiku S; Anzai T; Kobayashi T; Ishida H
    Clin Calcium; 2005 Sep; 15 Suppl 1():192-9. PubMed ID: 16279024
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
    Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
    J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal renewal and metabolic bone disease.
    Harris WH; Heaney RP
    N Engl J Med; 1969 Jan; 280(5):253-9 contd. PubMed ID: 4883109
    [No Abstract]   [Full Text] [Related]  

  • 7. Low Ca2+ dialysate. Effects on bone metabolism in the course of paired filtration dialysis.
    Carozzi S; Nasini MG; Pietrucci A; Costa M; Mantero R
    ASAIO J; 1994; 40(3):M683-5. PubMed ID: 8555601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium and phosphorus metabolism in maintenance hemodialysis.
    Ritz E; Mehls O; Krempien B
    Adv Nephrol Necker Hosp; 1980; 9():71-108. PubMed ID: 6773320
    [No Abstract]   [Full Text] [Related]  

  • 10. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
    Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
    Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of decreasing dialysate magnesium in patients with chronic renal failure.
    Burnell JM; Teubner E
    Proc Clin Dial Transplant Forum; 1976 Nov 19-22; 6():191-8. PubMed ID: 1029885
    [No Abstract]   [Full Text] [Related]  

  • 12. XVIII European symposium on calcified tissues. 15-18 October 1984. Angers, France. Abstracts.
    Calcif Tissue Int; 1984; 36 Suppl 2():S1-86. PubMed ID: 6435842
    [No Abstract]   [Full Text] [Related]  

  • 13. Is 2.5 mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines.
    Izumi M; Shirai K; Ito K; Miyamoto T; Matsumoto A; Takenaka Y; Nakagawa K; Yamanashi T; Takamitsu Y; Nakanish T
    Ther Apher Dial; 2005 Feb; 9(1):24-31. PubMed ID: 15828902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dialysate calcium and fluoride on bone disease during regular hemodialysis.
    Jowsey J; Johnson WJ; Taves DR; Kelly PJ
    J Lab Clin Med; 1972 Feb; 79(2):204-14. PubMed ID: 5009710
    [No Abstract]   [Full Text] [Related]  

  • 15. Bone disease and soft tissue calcification in chronic peritoneal dialysis.
    Cangiano JL; Ramírez-González RE; Ramírez-Muxó O
    Am J Med Sci; 1972 Oct; 264(4):301-6. PubMed ID: 4647391
    [No Abstract]   [Full Text] [Related]  

  • 16. Metabolic bone disease in chronic renal failure. I. Dialyzed uremics.
    Huffer WE; Kuzela D; Popovtzer MM
    Am J Pathol; 1975 Mar; 78(3):365-84. PubMed ID: 1119535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metabolic bone diseases: various factors influencing bone resorption and osteogenesis--with special reference to the mechanism of action--calcitonin].
    Miki T; Morii H
    Nihon Rinsho; 1986 Nov; 44(11):2366-71. PubMed ID: 3029460
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic hemodialysis and dental disease.
    Rivas MA; Carl W; Albert DJ
    Proc Clin Dial Transplant Forum; 1972; 2():63-6. PubMed ID: 4681313
    [No Abstract]   [Full Text] [Related]  

  • 19. Guidelines for disorders of mineral metabolism and secondary hyperparathyroidism should not yet be modified.
    Ix JH; Quarles LD; Chertow GM
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):337-9. PubMed ID: 16932455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of dialysate calcium concentration in hemodialysis.
    Toussaint N; Cooney P; Kerr PG
    Hemodial Int; 2006 Oct; 10(4):326-37. PubMed ID: 17014507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.